← Back to Clinical Trials
Recruiting NCT06363435
AI-based Measurements of Tumour Burden in PSMA PET-CT
Trial Parameters
Condition Prostate Cancer
Sponsor Elin Tragardh
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,500
Sex MALE
Min Age 20 Years
Max Age 120 Years
Start Date 2024-03-29
Completion 2031-03
Interventions
AI-based detection and quantification of suspected tumour/metastases in PSMA PET/CT scans
Brief Summary
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).
Eligibility Criteria
Inclusion Criteria: * Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden Exclusion Criteria: * Patients under 20 years old